All News

In this opening segment, Ravi D. Chauhan, MD, FACS, and R. Jonathan Henderson, MD, discuss how underreporting of CIS in pathology reports may limit access to guideline-supported therapies for patients with NMIBC.

Adam B. Weiner, MD, is joined by Nikita R. Bhatt, MBBS, MCh, MMed, FRCS, to discuss the WASHOUT study, a prospective international collaboration examining outcomes among patients admitted with emergency hematuria.

The FDA has granted 510(k) clearance to the Glean Abdominal Sensor, expanding the capabilities of the Glean Urodynamics System.

Maria Carmen Mir, MD, PhD, discusses how phase 3 trials of BCG/ICI combinations are shaping the future of high-risk NMIBC management, emphasizing the need for a more selective approach to treatment intensification.

Charles R. Powell, MD, highlights 12-month data on the Neuspera System for urge urinary incontinence, reflecting on ideal candidates and the treatment's role alongside other SNM options.

In a multisite validation study, the urine-based MPS2-AS assay outperformed mpMRI for detecting disease upgrading in men with GG1 prostate cancer on active surveillance and could reduce unnecessary biopsies.

Martin Gleave, MD, FRCSC, FACS, explains how the adaptive, biomarker-driven GUNS trial uses neoadjuvant therapy to link genomic subtypes with treatment response.

Advances in laser technology, morcellator design, and anesthetic approach have substantially improved HoLEP efficiency and patient recovery over the past decade, while surgeon-owned procedural checklists and pre-morcellation hemostasis remain the most critical safety practices for avoiding morcellator injury.

A recap of the FDA submissions and regulatory decisions in urology from April 2026.

In this episode, host Adam B. Weiner, MD, is joined by Maarten Albersen, MD, PhD, for a focused discussion on the evolving molecular landscape of penile cancer.

The FDA Oncologic Drugs Advisory Committee voted 7-1-1 in support of a favorable risk-benefit profile for capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC.

Findings from the HIFI-2 study suggest that salvage HIFU provides meaningful mid-term oncologic control with an acceptable safety profile in patients with localized prostate cancer recurrence after radiotherapy.

The phase 2 trial will assess the safety and efficacy of ViXe, a product designed to deliver botulinum toxin directly into the bladder wall.

Neoadjuvant sacituzumab govitecan plus pembrolizumab yielded a clinical complete response rate of 39%, supporting the potential for bladder preservation.

In this episode, Adam B. Weiner, MD, sits down with Giorgio Gandaglia, MD, to discuss the ongoing controversy surrounding pelvic lymph node dissection in prostate cancer.

Phase 1 data on 225Ac–J591 showed encouraging antitumor activity with manageable toxicity in patients with mCRPC.

Data from the CANOPY trial showed promising activity and manageable safety with cabozantinib plus nivolumab in mCRPC.

Phase 3 LITESPARK-012 shows adding belzutifan or quavonlimab to pembrolizumab-lenvatinib fails to boost survival in first-line advanced clear cell RCC.

The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of JANX014 in patients with mCRPC.

The FDA granted priority review to EV plus pembrolizumab as a perioperative regimen for cisplatin-eligible MIBC based on KEYNOTE-B15 data showing a 47% reduction in EFS events, a 35% reduction in the risk of death, and a pCR rate of 55.8% vs 32.5% with standard chemotherapy.

"Parastomal hernia repair can be performed either open or robotically, according to the surgeon’s preference. The 2 mainstays of repair are the keyhole and intraperitoneal Sugarbaker repairs," Wyre writes.

In this episode of The UroOnc Minute, host Adam B. Weiner, MD, is joined by Dr Alfonso Gómez de Liaño Lista for a timely discussion on a practice-changing development in muscle-invasive bladder cancer: the phase 3 KEYNOTE-B15 trial.

In this first installment of a 2-part interview, guideline chair professor Axel Heidenreich outlines key updates in the management of testicular cancer, with a strong focus on deintensification.